El Vínculo El Vínculo.
Direct award European Union Services

Analyse an DNA Proben (Next Generation Sequencing)

Buyer: Universitätsklinikum Heidelberg

Published
23 July 2024
Place of performance
DE125
Procedure
Negotiated procedure
Lots
1
Notice number
00441548-2024
Reference
51acfa2b-493f-4dcd-b459-5cf4925a8f6d
Official source
Official source

CPV codes

Description

In der GMMG-HD8/DSMM XIX-Studie ist die Rate der messbaren Resterkrankung mit der Sensitivität von 1x10^-5 (also eine Myelomzelle in 100.000 Zellen) ein sekundärer Studienendpunkt. Adaptive Biotechnologies ist der Alleinanbieter des Assays zur NGS (Next Generation Sequencing)-basierten Bestimmung der messbaren Resterkrankung beim Multiplen Myelom. Die aus den Knochenmarkzellen der Patienten gewonnene DNA wird daher nach der Aufbereitung im GMMG-Zentrallabor nach Seattle zu Adaptive Biotechnologies verschickt.

Award criteria

Official publications

Other tenders from Universitätsklinikum Heidelberg

Frequently asked questions

Who is the buyer of this tender?
The contracting authority is Universitätsklinikum Heidelberg (European Union).
How can I bid for public tenders in European Union?
Bids are submitted through the official procurement portal of European Union. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
Get alerts for tenders like this
Create a free account and receive new tenders from European Union matching your business, every day.

Start for free

Data collected from official public procurement sources. Amounts as published by the buyer.